Comparative analysis of age in monocrotaline-induced pulmonary hypertensive rats

Journal of Pharmacological Sciences

Moe Fujiwara¹  Akiko Kawade²  Saki Kobayashi²  Hisao Yamamura²  Yoshiaki Suzuki²  Chihiro Horii³  Shiho Mori³  Rubii Kondo³  Kikuo Tsukamoto³  Naoki Ohara³  Akari Hiraku³  Sayo Suzumura³  Aya Yamamura⁴ 

[1] Department of Pharmacy, College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori Moriyamaku, Nagoya, 463-8521, Japan;Department of Molecular and Cellular Pharmacology, Graduate School of Pharmaceutical Sciences, Nagoya City University, 3-1 Tanabedori Mizuhoku, Nagoya, 467-8603, Japan;Department of Pharmacy, College of Pharmacy, Kinjo Gakuin University, 2-1723 Omori Moriyamaku, Nagoya, 463-8521, Japan;Department of Physiology, Aichi Medical University, 1-1 Yazakokarimata, Nagakute, Aichi, 480-1195, Japan;

关键词: Pulmonary hypertension;    Monocrotaline;    Age;   

DOI  :  

来源: DOAJ

【 摘 要 】

Pulmonary arterial hypertension (PAH) is a rare, progressive, and fatal cardiovascular/lung disease. The incidence rate is affected by age. Monocrotaline (MCT, 60 mg/kg)-treated rats are widely used as an experimental PAH model. Here, we found that young rats died at a mean of 23.4 days after MCT injection, whereas adult rats survived for over 42 days. However, young (7-week-old) and adult (20-week-old) MCT-treated rats developed PAH, and had upregulated Ca2+-sensing receptor and transient receptor potential canonical subfamily 6 channel expression in pulmonary arteries. The present study provides novel information for elucidating the mechanism underlying the age difference in PAH patients.

【 授权许可】

Unknown